The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy

In the era of immune checkpoint blockade cancer therapy, cytokines have become an attractive immune therapeutics to increase response rates. Interleukin 21 (IL21) as a single agent has been evaluated for cancer treatment with good clinical efficacy. However, the clinical application of IL21 is limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shaoxian, Sun, Runzi, Tan, Bo, Chen, Bendong, Zhou, Wenyan, Gao, David Shihong, Zhong, Joshua, Huang, Hao, Jiang, Jingting, Lu, Binfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634682/
https://www.ncbi.nlm.nih.gov/pubmed/34869384
http://dx.doi.org/10.3389/fcell.2021.779865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634682/
https://www.ncbi.nlm.nih.gov/pubmed/34869384
http://dx.doi.org/10.3389/fcell.2021.779865

Ejemplares similares